Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.
Research output: Contribution to journal › Journal article › Research › peer-review
Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 microg s.c. for at least 12 weeks. Fifteen patients (40.5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin <100 IU/l, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.
Original language | English |
---|---|
Journal | British Journal of Haematology |
Volume | 128 |
Issue number | 2 |
Pages (from-to) | 204-9 |
Number of pages | 5 |
ISSN | 0007-1048 |
DOIs | |
Publication status | Published - 2005 |
Bibliographical note
Keywords: Aged; Anemia; Erythrocyte Count; Erythropoietin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Pilot Projects
ID: 8463333